Treatment for Barrett’s Esophagus, Reflux Disease


Treatment for Barrett’s Esophagus, Reflux Disease

Treatment for Barrett’s Esophagus, Reflux Disease is a potentially cancerous chronic inflammation of the esophagus. Barrett’s esophagus is typically caused by gastroesophageal reflux disease and patients who underwent a therapy called multipolar electrocoagulation, a safe and efficient procedure to ablate nondysplastic (Barrett’s esophagus) over the long term.


Electrocoagulation, which uses heat to remove the affected tissue so that new, healthy tissue can replace it, may decrease the risk for progression to cancer more than standard treatment involving acid suppression medication and endoscopic surveillance.

Barrett’s esophagus is a condition where the lining of the esophagus modifications because of chronic inflammation, due to gastroesophageal reflux disease (GERD). In the setting of chronic acid exposure, the cellular structure of the lower esophageal lining changes to look more like the cells lining the intestines. Barrett’s esophagus itself has no particular signs and symptoms, however this modification can increase the threat of esophageal adenocarcinoma (a kind of esophageal cancer).  Barrett’s esophagus can be easily identified during an upper endoscopy however needs to be validated by biopsies.


Researchers concluded that long-term follow-up of ablation of Barrett’s esophagus with multipolar electrocoagulation ablation treatment is a safe, effective approach to ablate Barrett’s esophagus over the long term. The number of sessions needed to attain total Barrett’s eradication ranged from 1 to 5. Ninety Five percent (95%) of patients had no recurrence of Barrett’s esophagus after preliminary ablation treatment was completed.